Skip to main content

Advertisement

Table 7 Prophylactic administration and adverse drug reactions to G-CSFs

From: A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors

Q20. Regarding the use of pegfilgrastim during 2-week interval chemotherapy, what kind of suggestion do you do? (N = 164)
 Use pegfilgrastim on the day of chemotherapy 2 (1.2)
 Use pegfilgrastim on the following day of chemotherapy 93 (56.7)
 Use pegfilgrastim on the following day of chemotherapy. I administer chemotherapy one day later of the next cycle, and use pegfilgrastim on the following day of chemotherapy 8 (4.9)
 Do not use pegfilgrastim 61 (37.2)
Q21.What explanation or suggestion do you provide for bone pain, an adverse drug reaction, in the use of G-CSFs? (N = 187)
 Do not explain about adverse events of G-CSFs to a patient 34 (18.2)
 Have a medical examination in the occurrence of bone pain 67 (35.8)
 Prescribe oral NSAIDs in advance of the occurrence of bone pain 85 (45.5)
 Prescribe oral antihistaminic drugs in advance in the occurrence of bone pain 1 (0.5)
Q22. Are G-CSFs used as primary prophylaxis at your institute? (N = 293)
 We used G-CSFs only during chemotherapy aimed at the symptom palliation 39 (13.3)
 We used G-CSFs only during chemotherapy aimed at achieving a cure or prolonging survival time 162 (55.3)
 We do not use G-CSFs as primary prophylaxis 92 (31.4)
  1. G-CSF Granulocyte-Colony Stimulating Factor, NSAIDs Non-Steroidal Anti-Inflammatory Drugs